Loading…
Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase
Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid a...
Saved in:
Published in: | Journal of medicinal chemistry 2023-01, Vol.66 (1), p.235-250 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983 |
---|---|
cites | cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983 |
container_end_page | 250 |
container_issue | 1 |
container_start_page | 235 |
container_title | Journal of medicinal chemistry |
container_volume | 66 |
creator | Intranuovo, Francesca Brunetti, Leonardo DelRe, Pietro Mangiatordi, Giuseppe Felice Stefanachi, Angela Laghezza, Antonio Niso, Mauro Leonetti, Francesco Loiodice, Fulvio Ligresti, Alessia Kostrzewa, Magdalena Brea, Jose Loza, Maria Isabel Sotelo, Eddy Saviano, Michele Colabufo, Nicola Antonio Riganti, Chiara Abate, Carmen Contino, Marialessandra |
description | Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents. |
doi_str_mv | 10.1021/acs.jmedchem.2c01084 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2757054448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2757054448</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1ERZfCGyDkYzlkO7GdTfYYtpRWaouE4Bw59nibyrGX2KkUTrwCj8Ir8SQ43W2PnEaa-f7_1-gn5F0OyxxYfiZVWN73qNUd9kumIIdKvCCLvGCQiQrES7IAYCxjK8aPyesQ7gGA54y_Isd8VQhW8dWC_DnHB7R-16OL1Bt6-_fX79M8q7XspYuT_dCi-yn7TmOgMtBbn2hau9hlV85Y2fcy-mGiN6ONXZTDFiOtt8kr0FrFzm1n0fkoLb3xerQzHOaYeId0I52Tbed8p-nmI6NfUeEuAVQ6TS9kjFPySLd6TqeXkx68lQHfkCMjbcC3h3lCvl98-ra5zK6_fL7a1NeZ5KKKmeGrtWmNASFaXpW60krkwNt12go0krfAWtDrkrMSSoVFaQrVskohlAzWFT8hp3vf3eB_jBhi03dBobXSoR9Dw8qihEIIMaNij6rBhzCgaXZD18thanJo5rKaVFbzVFZzKCvJ3h8SxjbdnkVP7SQA9sCj3I-DSw__3_MfYM-mxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2757054448</pqid></control><display><type>article</type><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</creator><creatorcontrib>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</creatorcontrib><description>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.2c01084</identifier><identifier>PMID: 36542836</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Amidohydrolases ; Anti-Inflammatory Agents - pharmacology ; Benzamides - pharmacology ; Cannabinoid Receptor Agonists ; Cannabinoids ; Endocannabinoids - metabolism ; Molecular Docking Simulation ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2</subject><ispartof>Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.235-250</ispartof><rights>2022 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</citedby><cites>FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</cites><orcidid>0000-0002-0713-3151 ; 0000-0001-9292-884X ; 0000-0003-3384-574X ; 0000-0001-9787-4836 ; 0000-0002-5523-1979 ; 0000-0003-4730-0863 ; 0000-0003-4042-2841 ; 0000-0003-1787-3900 ; 0000-0001-6221-6155 ; 0000-0002-9430-7972 ; 0000-0001-5571-2812 ; 0000-0001-5086-2459 ; 0000-0002-7787-6639 ; 0000-0001-5639-7746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36542836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Intranuovo, Francesca</creatorcontrib><creatorcontrib>Brunetti, Leonardo</creatorcontrib><creatorcontrib>DelRe, Pietro</creatorcontrib><creatorcontrib>Mangiatordi, Giuseppe Felice</creatorcontrib><creatorcontrib>Stefanachi, Angela</creatorcontrib><creatorcontrib>Laghezza, Antonio</creatorcontrib><creatorcontrib>Niso, Mauro</creatorcontrib><creatorcontrib>Leonetti, Francesco</creatorcontrib><creatorcontrib>Loiodice, Fulvio</creatorcontrib><creatorcontrib>Ligresti, Alessia</creatorcontrib><creatorcontrib>Kostrzewa, Magdalena</creatorcontrib><creatorcontrib>Brea, Jose</creatorcontrib><creatorcontrib>Loza, Maria Isabel</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><creatorcontrib>Saviano, Michele</creatorcontrib><creatorcontrib>Colabufo, Nicola Antonio</creatorcontrib><creatorcontrib>Riganti, Chiara</creatorcontrib><creatorcontrib>Abate, Carmen</creatorcontrib><creatorcontrib>Contino, Marialessandra</creatorcontrib><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</description><subject>Amidohydrolases</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Benzamides - pharmacology</subject><subject>Cannabinoid Receptor Agonists</subject><subject>Cannabinoids</subject><subject>Endocannabinoids - metabolism</subject><subject>Molecular Docking Simulation</subject><subject>Receptor, Cannabinoid, CB1</subject><subject>Receptor, Cannabinoid, CB2</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi1ERZfCGyDkYzlkO7GdTfYYtpRWaouE4Bw59nibyrGX2KkUTrwCj8Ir8SQ43W2PnEaa-f7_1-gn5F0OyxxYfiZVWN73qNUd9kumIIdKvCCLvGCQiQrES7IAYCxjK8aPyesQ7gGA54y_Isd8VQhW8dWC_DnHB7R-16OL1Bt6-_fX79M8q7XspYuT_dCi-yn7TmOgMtBbn2hau9hlV85Y2fcy-mGiN6ONXZTDFiOtt8kr0FrFzm1n0fkoLb3xerQzHOaYeId0I52Tbed8p-nmI6NfUeEuAVQ6TS9kjFPySLd6TqeXkx68lQHfkCMjbcC3h3lCvl98-ra5zK6_fL7a1NeZ5KKKmeGrtWmNASFaXpW60krkwNt12go0krfAWtDrkrMSSoVFaQrVskohlAzWFT8hp3vf3eB_jBhi03dBobXSoR9Dw8qihEIIMaNij6rBhzCgaXZD18thanJo5rKaVFbzVFZzKCvJ3h8SxjbdnkVP7SQA9sCj3I-DSw__3_MfYM-mxA</recordid><startdate>20230112</startdate><enddate>20230112</enddate><creator>Intranuovo, Francesca</creator><creator>Brunetti, Leonardo</creator><creator>DelRe, Pietro</creator><creator>Mangiatordi, Giuseppe Felice</creator><creator>Stefanachi, Angela</creator><creator>Laghezza, Antonio</creator><creator>Niso, Mauro</creator><creator>Leonetti, Francesco</creator><creator>Loiodice, Fulvio</creator><creator>Ligresti, Alessia</creator><creator>Kostrzewa, Magdalena</creator><creator>Brea, Jose</creator><creator>Loza, Maria Isabel</creator><creator>Sotelo, Eddy</creator><creator>Saviano, Michele</creator><creator>Colabufo, Nicola Antonio</creator><creator>Riganti, Chiara</creator><creator>Abate, Carmen</creator><creator>Contino, Marialessandra</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0713-3151</orcidid><orcidid>https://orcid.org/0000-0001-9292-884X</orcidid><orcidid>https://orcid.org/0000-0003-3384-574X</orcidid><orcidid>https://orcid.org/0000-0001-9787-4836</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-4730-0863</orcidid><orcidid>https://orcid.org/0000-0003-4042-2841</orcidid><orcidid>https://orcid.org/0000-0003-1787-3900</orcidid><orcidid>https://orcid.org/0000-0001-6221-6155</orcidid><orcidid>https://orcid.org/0000-0002-9430-7972</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0001-5086-2459</orcidid><orcidid>https://orcid.org/0000-0002-7787-6639</orcidid><orcidid>https://orcid.org/0000-0001-5639-7746</orcidid></search><sort><creationdate>20230112</creationdate><title>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</title><author>Intranuovo, Francesca ; Brunetti, Leonardo ; DelRe, Pietro ; Mangiatordi, Giuseppe Felice ; Stefanachi, Angela ; Laghezza, Antonio ; Niso, Mauro ; Leonetti, Francesco ; Loiodice, Fulvio ; Ligresti, Alessia ; Kostrzewa, Magdalena ; Brea, Jose ; Loza, Maria Isabel ; Sotelo, Eddy ; Saviano, Michele ; Colabufo, Nicola Antonio ; Riganti, Chiara ; Abate, Carmen ; Contino, Marialessandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amidohydrolases</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Benzamides - pharmacology</topic><topic>Cannabinoid Receptor Agonists</topic><topic>Cannabinoids</topic><topic>Endocannabinoids - metabolism</topic><topic>Molecular Docking Simulation</topic><topic>Receptor, Cannabinoid, CB1</topic><topic>Receptor, Cannabinoid, CB2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Intranuovo, Francesca</creatorcontrib><creatorcontrib>Brunetti, Leonardo</creatorcontrib><creatorcontrib>DelRe, Pietro</creatorcontrib><creatorcontrib>Mangiatordi, Giuseppe Felice</creatorcontrib><creatorcontrib>Stefanachi, Angela</creatorcontrib><creatorcontrib>Laghezza, Antonio</creatorcontrib><creatorcontrib>Niso, Mauro</creatorcontrib><creatorcontrib>Leonetti, Francesco</creatorcontrib><creatorcontrib>Loiodice, Fulvio</creatorcontrib><creatorcontrib>Ligresti, Alessia</creatorcontrib><creatorcontrib>Kostrzewa, Magdalena</creatorcontrib><creatorcontrib>Brea, Jose</creatorcontrib><creatorcontrib>Loza, Maria Isabel</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><creatorcontrib>Saviano, Michele</creatorcontrib><creatorcontrib>Colabufo, Nicola Antonio</creatorcontrib><creatorcontrib>Riganti, Chiara</creatorcontrib><creatorcontrib>Abate, Carmen</creatorcontrib><creatorcontrib>Contino, Marialessandra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Intranuovo, Francesca</au><au>Brunetti, Leonardo</au><au>DelRe, Pietro</au><au>Mangiatordi, Giuseppe Felice</au><au>Stefanachi, Angela</au><au>Laghezza, Antonio</au><au>Niso, Mauro</au><au>Leonetti, Francesco</au><au>Loiodice, Fulvio</au><au>Ligresti, Alessia</au><au>Kostrzewa, Magdalena</au><au>Brea, Jose</au><au>Loza, Maria Isabel</au><au>Sotelo, Eddy</au><au>Saviano, Michele</au><au>Colabufo, Nicola Antonio</au><au>Riganti, Chiara</au><au>Abate, Carmen</au><au>Contino, Marialessandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2023-01-12</date><risdate>2023</risdate><volume>66</volume><issue>1</issue><spage>235</spage><epage>250</epage><pages>235-250</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36542836</pmid><doi>10.1021/acs.jmedchem.2c01084</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-0713-3151</orcidid><orcidid>https://orcid.org/0000-0001-9292-884X</orcidid><orcidid>https://orcid.org/0000-0003-3384-574X</orcidid><orcidid>https://orcid.org/0000-0001-9787-4836</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-4730-0863</orcidid><orcidid>https://orcid.org/0000-0003-4042-2841</orcidid><orcidid>https://orcid.org/0000-0003-1787-3900</orcidid><orcidid>https://orcid.org/0000-0001-6221-6155</orcidid><orcidid>https://orcid.org/0000-0002-9430-7972</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0001-5086-2459</orcidid><orcidid>https://orcid.org/0000-0002-7787-6639</orcidid><orcidid>https://orcid.org/0000-0001-5639-7746</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.235-250 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_2757054448 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | Amidohydrolases Anti-Inflammatory Agents - pharmacology Benzamides - pharmacology Cannabinoid Receptor Agonists Cannabinoids Endocannabinoids - metabolism Molecular Docking Simulation Receptor, Cannabinoid, CB1 Receptor, Cannabinoid, CB2 |
title | Development of N‑(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A47%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20N%E2%80%91(1-Adamantyl)benzamides%20as%20Novel%20Anti-Inflammatory%20Multitarget%20Agents%20Acting%20as%20Dual%20Modulators%20of%20the%20Cannabinoid%20CB2%20Receptor%20and%20Fatty%20Acid%20Amide%20Hydrolase&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Intranuovo,%20Francesca&rft.date=2023-01-12&rft.volume=66&rft.issue=1&rft.spage=235&rft.epage=250&rft.pages=235-250&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.2c01084&rft_dat=%3Cproquest_cross%3E2757054448%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a348t-f369fbff044b387d8dc4103b99fb4efa3b02b0d9732707ce57f5cb28ce0720983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2757054448&rft_id=info:pmid/36542836&rfr_iscdi=true |